2-ethynylbicyclo[2.2.1]heptan-2-ol | 18084-03-2

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 异戊烯醇脂质
• 英文名称: 2-ethynylbicyclo[2.2.1]heptan-2-ol
• 英文别名: 2-Hydroxy-2-aethinyl-norbornan
• CAS: 18084-03-2
• 化学式: C₉H₁₂O
• 分子量: 136.194
• InChiKey: DOBPSJXGDUDHTH-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.2
• 重原子数：
  10
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.78
• 拓扑面积：
  20.2
• 氢给体数：
  1
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  2-ethynylbicyclo[2.2.1]heptan-2-ol 在 氢氧化钾 、 potassium permanganate 、 phosphorus pentoxide 作用下， 以 苯 为溶剂， 生成 1,3-环戊二羧酸
  参考文献：
  名称：

  Kagawa,M., Chemical and pharmaceutical bulletin, 1961, vol. 9, p. 391 - 403

  摘要：

  DOI：
• 作为产物：
  描述：

  降樟脑 、 乙炔锂乙二胺配合物 在 水 作用下， 以 四氢呋喃 为溶剂， 反应 18.0h， 生成 2-ethynylbicyclo[2.2.1]heptan-2-ol
  参考文献：
  名称：

  N-ARYL-SUBSTITUTED CYCLIC AMINE DERIVATIVE AND MEDICINE CONTAINING THE SAME AS ACTIVE INGREDIENT

  摘要：

  公开号：

  EP1375496B1

文献信息

• 6,5-HETEROCYCLIC PROPARGYLIC ALCOHOL COMPOUNDS AND USES THEREFOR
  申请人：Staben Steven

  公开号：US20120214762A1

  公开（公告）日：2012-08-23

  The invention relates to novel compounds of Formula I: wherein A, Y, R 1 , R 2 and the subscript b each has the meaning as described herein and compounds of Formula I, and stereoisomers, geometric isomers, tautomers, solvates, metabolites, isotopes, pharmaceutically acceptable salts, or prodrugs thereof. Compounds of Formula I and pharmaceutical compositions thereof are useful in the treatment of disease and disorders in which undesired or over-activation of NF-kB signaling is observed.

  这项发明涉及公式I的新化合物： 其中A、Y、R1、R2和下标b各自具有如本文所述的含义，以及公式I的化合物、立体异构体、几何异构体、互变异构体、溶剂合物、代谢物、同位素、药学上可接受的盐或其前药。公式I的化合物及其药物组成物在治疗观察到NF-kB信号通路的不良或过度激活的疾病和紊乱中是有用的。
• N-aryl-substituted cyclic amine derivative and medicine containing the same as active ingredient
  申请人：——

  公开号：US20040072830A1

  公开（公告）日：2004-04-15

  The present invention provides an excellent squalene synthase inhibitor. Specifically, it provides a compound (I) represented by the following formula, a salt thereof or a hydrate of them. 1 wherein R 1 represents an optionally substituted vinyl group or an aromatic ring which may be substituted; n is an integer of 0 to 2; X, Y and Z are the same as or different from each other and each represents an optionally substituted carbon atom, or an optionallysubstitutednitrogenatom, sulfuratomoroxygenatom, and Y optionally represents a single bond, and when Y represents the single bond, the ring to which X, Y and Z belong is a 5-membered ring; CyA represents a 5- to 14 membered non-aromatic cyclic amino groupornon-aromatic cyclic amidogroupwhichmaybe substituted, and the non-aromatic cyclic amino group or the non-aromatic cyclic amido group optionally having an oxygen atom or a sulfur atom; W represents a chain expressed by (1) optionally substituted -CH 2 -CH 2 -, (2) optionally substituted -CH=CH-, (3) -C-C-, (4) an optionally substituted phenylene group, (5) a single bond, (6) -NH-CO-, (7) -CO-NH-, (8) -NH-CH 2 -, (9) -CH 2 -NH-, (10) -CH 2 -CO-, (11) -CO-CH 2 -, (12) -O-(CH 2 ) m 1 (13) - (CH 2 ) -O- (where m represents an integer of 0 to 5), (14) -O-CH 2 -CR 2 =1 (15) -O-CH 2 -CHR 2 - (where R 2 represents a hydrogen atom, a C 16 alkyl group or a halogen atom), (16) -NH-S(O)l-, (17) -S(O)3l-NH-, (18) -CH 2 -S(°) 1 -. or (19) -S(O),-CH 2 - (where 1 represents 0, 1, or 2); and A represents a group having any of the following structural formulae: 2 (wherein R 3 and R 4 represent independently a hydrogen atom or an optionally substituted C 16 alkyl group, or combine through a carbon chain optionally containing a heteroatom to form a ring; R 5 and R 6 represent independently a hydrogen atom or an optionally substituted C 16 alkyl group, or combine through a carbon chain optionally containing a heteroatom to form a ring; R 7 represents a hydrogen atom, an optionally substituted C 16 alkyl group, a hydroxyl group, an alkoxy group, a halogen atom or an optionally substituted amino group; R 8 represents a hydrogen atom, a hydroxyl group, an alkoxy group, a halogen atom or an optionally substituted amino group; B1 represents an optionally substituted carbon atom, or an optionallysubstitutednitrogenatom, oxygenatomorsulfuratom; B2 represents an optionally substituted carbon atom or nitrogen atom; a and b represent an integer of 0 to 4, provided that a+b is an integer of 0 to 4; c represents 0 or 1; and 3 represents a single bond or a double bond, provided that when c is 1 in which A is a quinuclidine having R 8 represented by 4 the case where R 8 is a hydrogen atom or a hydroxyl group; Arl is an aromatic heterocycle; and W is one of (1) to (3), (6) to (11) and (16) to (19) are excluded).

  本发明提供了一种出色的角鲨烷合成酶抑制剂。具体地，提供了以下式子所表示的化合物（I），其盐或水合物。 其中，R1表示可以被取代的乙烯基或可以被取代的芳香环，n为0至2的整数；X、Y和Z相同或不同，每个表示可以被取代的碳原子、可以被取代的氮原子、硫原子或氧原子，Y可以表示单键，当Y表示单键时，X、Y和Z所属的环是一个五元环；CyA表示一个5-至14个成员的非芳香环状氨基团或非芳香环状酰胺基团，其可以被取代，非芳香环状氨基团或非芳香环状酰胺基团可以选择具有氧原子或硫原子；W表示由以下式子表示的链： （1）可以被取代的-CH2-CH2-， （2）可以被取代的-CH=CH-， （3）-C-C-， （4）可以被取代的苯基， （5）单键， （6）-NH-CO-， （7）-CO-NH-， （8）-NH-CH2-， （9）-CH2-NH-， （10）-CH2-CO-， （11）-CO-CH2-， （12）-O-（CH2）m1（其中m表示0至5的整数）， （13）-（CH2）-O-（其中m表示0至5的整数）， （14）-O-CH2-CR2=1， （15）-O-CH2-CHR2-（其中R2表示氢原子、C16烷基或卤素原子）， （16）-NH-S(O)l-， （17）-S(O)3l-NH-， （18）-CH2-S(°)1-或 （19）-S(O),-CH2-（其中l表示0、1或2）； A表示以下结构式之一的基团： （其中，R3和R4独立地表示氢原子或可以被取代的C16烷基，或通过可选含有杂原子的碳链结合形成环；R5和R6独立地表示氢原子或可以被取代的C16烷基，或通过可选含有杂原子的碳链结合形成环；R7表示氢原子、可以被取代的C16烷基、羟基、烷氧基、卤素原子或可以被取代的氨基团；R8表示氢原子、羟基、烷氧基、卤素原子或可以被取代的氨基团；B1表示可以被取代的碳原子、可以被取代的氮原子、氧原子或硫原子；B2表示可以被取代的碳原子或氮原子；a和b表示0至4的整数，前提是a+b是0至4的整数；c表示0或1；3表示单键或双键，当c为1时，A为具有R8由4表示的喹啉环的情况除外，Arl为芳香杂环，而W为（1）至（3）、（6）至（11）和（16）至（19）中的一种。
• 6,5-Heterocyclic Propargylic Alcohol Compounds and Uses Therefor
  申请人：Genentech, Inc.

  公开号：US20150038460A1

  公开（公告）日：2015-02-05

  The invention relates to novel compounds of Formula I: wherein A, Y, R 1 , R 2 and the subscript b each has the meaning as described herein and compounds of Formula I, and stereoisomers, geometric isomers, tautomers, solvates, metabolites, isotopes, pharmaceutically acceptable salts, or prodrugs thereof. Compounds of Formula I and pharmaceutical compositions thereof are useful in the treatment of disease and disorders in which undesired or over-activation of NF-kB signaling is observed.

  该发明涉及公式I的新化合物：其中A，Y，R1，R2和下标b各自具有如下所述的含义，以及公式I的化合物，立体异构体，几何异构体，互变异构体，溶剂化物，代谢物，同位素，药学上可接受的盐或其前药。公式I的化合物及其制药组合物在治疗疾病和障碍方面有用，其中观察到NF-kB信号不良或过度激活。
• 6,5-heterocyclic propargylic alcohol compounds and uses therefor
  申请人：Staben Steven

  公开号：US08901313B2

  公开（公告）日：2014-12-02

  The invention relates to novel compounds of Formula I: wherein A, Y, R1, R2 and the subscript b each has the meaning as described herein and compounds of Formula I, and stereoisomers, geometric isomers, tautomers, solvates, metabolites, isotopes, pharmaceutically acceptable salts, or prodrugs thereof. Compounds of Formula I and pharmaceutical compositions thereof are useful in the treatment of disease and disorders in which undesired or over-activation of NF-kB signaling is observed.

  本发明涉及一种新型化合物I的公式：其中A，Y，R1，R2和下标b具有如下所述的含义，以及化合物I的立体异构体，几何异构体，互变异构体，溶剂化物，代谢物，同位素，药学上可接受的盐或其前药。公式I化合物及其制药组合物在治疗疾病和障碍方面有用，其中观察到NF-kB信号的不良或过度激活。
• Back Pocket Flexibility Provides Group II p21-Activated Kinase (PAK) Selectivity for Type I 1/2 Kinase Inhibitors
  作者：Steven T. Staben、Jianwen A. Feng、Karen Lyle、Marcia Belvin、Jason Boggs、Jason D. Burch、Ching-ching Chua、Haifeng Cui、Antonio G. DiPasquale、Lori S. Friedman、Christopher Heise、Hartmut Koeppen、Adrian Kotey、Robert Mintzer、Angela Oh、David Allen Roberts、Lionel Rouge、Joachim Rudolph、Christine Tam、Weiru Wang、Yisong Xiao、Amy Young、Yamin Zhang、Klaus P. Hoeflich

  DOI：10.1021/jm401768t

  日期：2014.2.13

  Structure-based methods were used to design a potent and highly selective group II p21-activated kinase (PAK) inhibitor with a novel binding mode, compound 17. Hydrophobic interactions within a lipophilic pocket past the methionine gatekeeper of group II PAKs approached by these type I 1/2 binders were found to be important for improving potency. A structure-based hypothesis and strategy for achieving selectivity over group I PAKs, and the broad kinome, based on unique flexibility of this lipophilic pocket, is presented. A concentration-dependent decrease in tumor cell migration and invasion in two triple-negative breast cancer cell lines was observed with compound 17.